Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

21 Months Ended

Jun. 29, 2025

Jun. 30, 2024

Jun. 29, 2025

Jun. 30, 2024

Jun. 29, 2025

Restructuring Cost and Reserve [Line Items]

Restructuring charges

^[1]

$ (74)

$ 1,104

$ 547

$ 1,114

Productivity and Operational Efficiencies [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges

Biopharma [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges

(406)

1,100

211

1,100

Realigning Our Cost Base Program [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

5,300

$ 5,300

Restructuring cost incurred to date

3,500

Realigning Our Cost Base Program [Member] | Biopharma [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

3,700

Restructuring cost incurred to date

2,700

Restructuring charges

(25)

(113)

562

(199)

2,500

Realigning Our Cost Base Program - Initial Phase [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

3,100

Realigning Our Cost Base Program - Initial Phase [Member] | Biopharma [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

2,400

Realigning Our Cost Base Program - Selling, Informational and Administrative Initiative [Member] | Productivity and Operational Efficiencies [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

1,600

Realigning Our Cost Base Program - Selling, Informational and Administrative Initiative [Member] | Biopharma [Member] | Productivity and Operational Efficiencies [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

700

Realigning Our Cost Base Program - Research and Development [Member] | Biopharma [Member] | Productivity and Operational Efficiencies [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

600

Manufacturing Optimization Program [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring cost incurred to date

850

Manufacturing Optimization Program [Member] | Biopharma [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges

(408)

$ 1,300

(412)

$ 1,300

Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member]

Restructuring Cost and Reserve [Line Items]

Expected restructuring cost

$ 1,400

[1]

Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program), (ii) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program) and (iii) charges of $1.1 billion for both the three and six months ended June 30, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program for both periods presented and credits of $113 million for the three months and $199 million for the six months ended June 30, 2024 for our Realigning our Cost Base Program). For all periods presented, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.

PFIZER INC 10-Q